Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Slides 20 37 -vulnerable patient with movies


Published on

SHAPE Society

Published in: Health & Medicine
  • Login to see the comments

  • Be the first to like this

Slides 20 37 -vulnerable patient with movies

  1. 1. Writer and Director: Morteza Naghavi, MD Design and Animation: Mark Johnson Music: Eric Jarvis Click here to escape the movie Click to view the Natural History of Atherosclerosis and Vulnerable Plaques
  2. 2. Naghavi et al. Circulation. 2003;108:1664 Both Morphology and Activity Assessments are Needed
  3. 3. Naghavi et al. Circulation. 2003;108:1664 • Abnormal lipoprotein profile (e.g. high LDL, low HDL, abnormal LDL and HDL size density, lipoprotein (a), Lp-PLA2 …) • Serum markers of insulin resistance syndrome (e.g. diabetes, hyper triglyceridemia ) • Non-specific markers of inflammation (e.g. hsCRP, CD40L, ICAM-1, VCAM-1, P-selectin, leukocytosis, and other serologic markers related to the immune system. These markers may not be specific for atherosclerosis or plaque inflammation) • Specific markers of immune activation (e.g. anti-LDL antibody, anti-HSP antibody) • Markers of lipid-peroxidation (e.g. ox-LDL and ox-HDL) • Homocysteine • Pregnancy-associated plasma protein A (PAPP-A) • Circulating apoptosis marker(s) (e.g., Fas/Fas ligand, not specific to plaque) • Asymmetric dimethylarginine (ADMA) / dimethylarginine dimethylaminohydrolase (DDAH) • Circulating nonesterified fatty acids (e.g. NEFA) Serologic Markers of Vulnerability (Reflecting Metabolic and Immune Disorders)
  4. 4. • Markers of blood hypercoagulability (e.g. fibrinogen, D-dimer, and factor V Leiden) • Increased platelet activation and aggregation (e.g., gene polymorphisms of platelet glycoproteins IIb/IIIa, Ia/IIa, and Ib/IX) • Increased coagulation factors (e.g., clotting of factors V, VII, VIII, von Willebrand factor, XIII) • Decreased anticoagulation factors (e.g., proteins S, C, thrombomodulin, and antithrombin III) • Decreased endogenous fibrinolysis activity (e.g. reduced t-PA, increased PAI- 1, certain PAI-1 polymorphisms) • Prothrombin mutation (e.g. G20210A) • Other thrombogenic factors (e.g., anticardiolipin antibodies, thrombocytosis, sickle cell disease, polycythemia, diabetes mellitus, hypercholesterolemia, hyperhomocysteinemia) • Increased viscosity • Transient hypercoagulability (e.g. smoking, dehydration, infection, adrenergic surge, cocaine, estrogens, postprandial, etc.) Blood Markers of Vulnerability (Reflecting Hypercoagulability) Naghavi et al. Circulation. 2003;108:1664
  5. 5. With atherosclerosis-derived myocardial ischemia as shown by: ECG abnormalities: - During rest - During stress test - Silent ischemia (e.g. ST changes on Holter monitoring) Perfusion and viability disorder: - PET scan - SPECT Wall motion abnormalities: - Echocardiography - MR imaging - X-ray ventriculogram - MSCT Naghavi et al. Circulation. 2003;108:1664 Conditions and Markers Associated with Myocardial Vulnerability
  6. 6. Without atherosclerosis-derived myocardial ischemia: • Sympathetic hyperactivity • Impaired arterial baroreflex • Left ventricular hypertrophy • Cardiomyopathy (dilated, hypertrophic, restrictive, or right ventricular) • Valvular disease (aortic stenosis and mitral valve prolapse) • Electrophysiologic disorders: - Long QT syndrome, Brugada syndrome, Wolff-Parkinson-White syndrome, sinus and atrioventricular conduction disturbances, catecholaminergic polymorphic ventricular tachycardia, T-wave alternans, drug-induced torsades de pointes • Commotio cordis • Anomalous origination of a coronary artery • Myocarditis • Myocardial bridging Naghavi et al. Circulation. 2003;108:1664 Conditions and Markers Associated with Myocardial Vulnerability
  7. 7. Diagnostic Criteria: - Arrhythmia - QT dispersion - QT dynamics - T wave alternans - Ventricular late potentials - Heart rate variability Diagnostic Techniques: Non-Invasive: Resting ECG Stress ECG Ambulatory ECG Signal averaged electrocardiogram (SAECG) Surface high-resolution ECG Invasive: Programmed ventricular stimulation (PVS) Real-time 3D magnetic-navigated activation map Available Techniques for Electrophysiologic Risk Stratification of Vulnerable Myocardium Naghavi et al. Circulation. 2003;108:1664
  8. 8. Naghavi et al. Circulation. 2003;108:1664
  9. 9. Click here to escape the movie Click to view the Vulnerable Plaque-Blood-Myocardium Movie
  10. 10. The VP Pyramid Screening >> Diagnosis Treatment>> Outlines for Annual
  11. 11. CVD Genotyping? Naghavi et al. Circulation. 2003;108:1664
  12. 12. Out-of- hospital screening (EF, serum tests, physician visit) Non-Invasive Imaging Diagnostic Cath Drug-Eluting Stent Statin and other Drugs
  13. 13. Annual Cost of Heart Attacks in the USA
  14. 14. Stay Tuned for the Guidelines Screening >> Diagnosis Treatment>> in Part III and IV